Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 225 of 900 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/30/14
End: 12/31/15
Due: 12/31/16
Phase: N/A
Priority: Normal
Start: 01/23/18
End: 09/30/22
Due: 09/30/23
Phase: N/A
Priority: Normal
Start: 04/18/17
End: 02/03/23
Due: 02/03/24
Phase: N/A
Priority: Normal
Start: 05/01/25
End: 09/30/25
Due: 09/30/26
Phase: N/A
Priority: Normal
Start: 08/01/24
End: 07/31/27
Due: 07/31/28
Phase: N/A
Priority: Normal
Start: 09/30/00
End: 04/30/04
Due: 04/30/05
Phase: N/A
Priority: Normal
Start: 04/30/14
End: 03/31/16
Due: 03/31/17
Phase: N/A
Priority: Normal
Start: 03/08/18
End: 04/28/20
Due: 04/28/21
Phase: N/A
Priority: Normal
Start: 01/15/22
End: 03/31/22
Due: 03/31/23
Phase: N/A
Priority: Normal
Start: 10/20/20
End: 12/02/23
Due: 12/02/24
Phase: N/A
Priority: Normal
Start: 08/31/11
End: 04/30/13
Due: 04/30/14
Phase: N/A
Priority: Normal
Start: 07/01/15
End: 08/31/21
Due: 08/31/22
Phase: N/A
Priority: Normal
Start: 05/31/14
End: 07/31/20
Due: 07/31/21
Phase: N/A
Priority: Normal
Start: 09/30/06
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 03/07/23
End: 07/31/24
Due: 07/31/25
Phase: N/A
Priority: Normal
Start: 09/15/16
End: 06/30/19
Due: 06/30/20
Phase: N/A
Priority: Normal
Start: 06/30/08
End: 12/31/08
Due: 12/31/09
Phase: N/A
Priority: Normal
Start: 07/19/22
End: 12/30/26
Due: 12/30/27
Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
Phase: N/A
Priority: Normal
Start: 06/01/25
End: 12/01/26
Due: 12/01/27
Phase: N/A
Priority: Normal
Start: 04/03/25
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 06/01/20
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 06/07/21
End: 06/07/22
Due: 06/07/23
Phase: N/A
Priority: Normal
Start: 12/31/06
End: 12/31/08
Due: 12/31/09
Phase: N/A
Priority: Normal
Start: 06/17/24
End: 12/04/24
Due: 12/04/25
Phase: N/A
Priority: Normal
Start: 07/31/10
End: -
Due: -